Boehringer Ingelheim Partners with AnGes for HGF Gene Therapy

Boehringer Ingelheim has entered into a contract development and manufacturing agreement with AnGes Inc. for the active pharmaceutical ingredient of its investigational Hepatocyte Growth Factor (HGF) gene therapy. This therapy targets Peripheral Arterial Disease (PAD), a condition affecting more than 200 million people worldwide. The collaboration represents a significant step in advancing the development of this innovative treatment, building on nearly two decades of partnership between the two companies.

The agreement is particularly timely, following AnGes’ announcement earlier this month regarding the successful completion of clinical trials. The company plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) soon. Boehringer Ingelheim’s BioXcellence division will produce the plasmid DNA molecule using microbial technology in E. coli at its facility in Vienna, Austria.

Long-Standing Collaboration Enhances Development Efforts

The collaboration between Boehringer Ingelheim and AnGes began almost two decades ago, initially focusing on supplying materials for clinical trials. As the partnership has evolved, it has now reached a critical point with this new agreement. Ei Yamada, PhD, President & CEO of AnGes, expressed enthusiasm regarding the partnership, stating, “We proudly collaborate with Boehringer Ingelheim BioXcellence, one of the top manufacturers of drugs and biologics in the world, and look forward to our mutual efforts toward a successful FDA approval.”

Boehringer Ingelheim emphasizes that this partnership underscores its expertise in microbial contract development and manufacturing. The company remains committed to assisting its partners in achieving key regulatory milestones, such as obtaining BLA approval.

Significance of Gene Therapy for PAD Patients

AnGes has highlighted the potential benefits of early intervention for patients suffering from PAD, which can lead to severe complications including ulceration, infection, and amputation. The HGF gene therapy aims to address these challenges, and the company believes that strengthening their collaboration with Boehringer Ingelheim will facilitate accelerated development of this important treatment.

As the two companies work together toward regulatory approval, they aim to enhance the overall value of their innovative gene therapy, which could significantly improve the quality of life for millions affected by PAD around the globe.